Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, and Compass Minerals and Encourages Investors to Contact the Firm
April 30, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
COMPASS MINERALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Compass Minerals International, Inc. and Encourages Investors to Contact the Firm
April 26, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
April 16, 2024 08:00 ET
|
Compass Therapeutics
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a...
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
February 29, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 28, 2024 08:00 ET
|
Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Compass Therapeutics Provides Corporate Update
January 05, 2024 08:00 ET
|
Compass Therapeutics
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...
Compass Therapeutics to Participate in Upcoming Investor Events
November 07, 2023 08:00 ET
|
Compass Therapeutics
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Bespoke Metrics and Procore Deepen Collaboration to Streamline Preconstruction Phase
September 12, 2023 10:00 ET
|
Bespoke Metrics
TORONTO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- COMPASS by Bespoke Metrics, a leading provider of prequalification and risk management technology, today announced the integration of its prequalification...
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 26, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 02, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...